NEW YORK, NY--(Marketwire - Dec 14, 2011) - Today, [ www.BollingerReport.com ] introduced featured coverage of Keryx Biopharmaceuticals (NASDAQ: [ KERX ]) and AEterna Zentaris Inc. (USA) (NASDAQ: [ AEZS ]). Full research reports are available to readers at: [ www.BollingerReport.com/index.php?sm1=KERX&sm2=AEZS ].

Upcoming macro-economic 'tides of influence' are buoyed by crisis both home and abroad. Spanish and Italian yields continue to climb as efforts by the European Central Bank have stopped short of establishing sovereign bond guarantees for any one country. The result is historic yields and a grave concern for the solvency of interbank lending. Markets were drawn to concerns over domestic policy stalemates producing downgrade risks. Despite the situation, there continues to be unique value and opportunity found within careful discretion.

Bollinger Report screened and selected Keryx Biopharmaceuticals for its current position within the healthcare industry. Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. A copy of this report featuring Keryx Biopharmaceuticals (NASDAQ: [ KERX ]) is available at: [ www.BollingerReport.com/index.php?sm1=KERX ].

Bollinger Report is featuring AEterna Zentaris Inc. (USA) for its changing role within the healthcare industry. Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. To download researches and analysis on AEterna Zentaris Inc. (USA) (NASDAQ: [ AEZS ]) we welcome investors to visit: [ www.BollingerReport.com/index.php?sm2=AEZS ].

About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.